Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
APMIS ; 97(12): 1146-8, 1989 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2482060

RESUMEN

IgG subclass levels to Pseudomonas aeruginosa alginate, alkaline proteinase, elastase and exotoxin A in sera of healthy adults, non-infected and infected cystic fibrosis patients were investigated by enzyme linked immunosorbent assay. Whereas healthy adults and non-infected cystic fibrosis patients revealed mostly negative IgG subclass levels to the four antigens, infected cystic fibrosis patients had significantly elevated IgG1, IgG2, IgG3 and IgG4 levels to both the protein antigens as well as the polysaccharide antigen. The study does not support previous findings of an impaired natural IgG2 response to polysaccharide antigen. The study does not support previous findings of an impaired natural IgG2 response to polysaccharide in chronically infected cystic fibrosis patients.


Asunto(s)
ADP Ribosa Transferasas , Anticuerpos Antibacterianos/inmunología , Toxinas Bacterianas , Fibrosis Quística/inmunología , Inmunoglobulina G/inmunología , Polisacáridos Bacterianos/inmunología , Infecciones por Pseudomonas/inmunología , Pseudomonas aeruginosa/inmunología , Serina Endopeptidasas , Factores de Virulencia , Adolescente , Adulto , Alginatos , Niño , Preescolar , Fibrosis Quística/complicaciones , Endopeptidasas/inmunología , Ensayo de Inmunoadsorción Enzimática , Epítopos , Exotoxinas/inmunología , Humanos , Inmunoglobulina G/clasificación , Lactante , Elastasa Pancreática/inmunología , Infecciones por Pseudomonas/complicaciones , Pseudomonas aeruginosa/enzimología , Exotoxina A de Pseudomonas aeruginosa
2.
Med Klin (Munich) ; 95(12): 678-82, 2000 Dec 15.
Artículo en Alemán | MEDLINE | ID: mdl-11198555

RESUMEN

Streptococcus pneumoniae is the most common etiologic agent in outpatients pneumonia. Pneumococcal infections are often associated with high mortality risk in immunocompromised patients. An increasing resistance of Streptococcus pneumoniae to antibiotics is observed worldwide. This led to the official recommendation by the STIKO to use the vaccination in special risk groups. The commercially available 23-valent polysaccharide vaccine produces a reliable immune response against pneumococcal infection in children aged over 2 years and adults. The recommendation should be more realized in practice.


Asunto(s)
Vacunas Neumococicas/administración & dosificación , Neumonía Neumocócica/prevención & control , Adolescente , Adulto , Niño , Preescolar , Estudios Transversales , Femenino , Alemania , Humanos , Programas de Inmunización , Incidencia , Masculino , Neumonía Neumocócica/epidemiología , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda